Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 214

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial

Open access
Magrini, Stefano Maria, Buglione, Michela, Corvò, Renzo, Pirtoli, Luigi, Paiar, Fabiola, Ponticelli, Pietro, Petrucci, Alessia, Bacigalupo, Almalina, Crociani, Monica, Lastrucci, Luciana, Vecchio, Stefania, Bonomo, Pierluigi, Pasinetti, Nadia, Triggiani, Luca, Cavagnini, Roberta, Costa, Loredana, Tonoli, Sandro, Maddalo, Marta, Grisanti, Salvatore·2016·Journal of Clinical Oncology

Abstract

Purpose: No randomized trials have been conducted to directly compare radiotherapy (RT) with concomitant cisplatin (CDDP) versus concomitant cetuximab (CTX) as first-line treatment of locally advanced squamous cell carcinoma of the head and neck. In this randomized trial, we compared these two treatment regimens in terms of compliance, toxicity, and efficacy. Patients and Methods: Eligible patients were randomly assigned in a 1:1 ratio to receive either CDDP 40 mg/m 2 once per week or CTX 400 mg/m 2 as loading dose followed by CTX 250 mg/m 2 once per week concomitant to radical RT. For primary end points, compliance to treatment was defined as number of days of treatment discontinuation and drug dosage reduction. The acute toxicity rate was defined according to the National Cancer Institute Common Toxicity Criteria. Efficacy end points were local recurrence-free survival, metastasis-free survival, cancer-specific survival, and overall survival. Results: The study was discontinued early because of slow accrual after the enrollment of 70 patients. RT discontinuation for more than 10 days occurred in 13% of patients given CTX and 0% given CDDP (P = .05). Drug dosage reduction occurred in 34% given CTX and 53% given CDDP (difference not significant). Toxicity profiles differed between the two arms, with hematologic, renal, and GI toxicities more frequent in the CDDP arm, and cutaneous toxicity and the need for nutritional support more frequent in the CTX arm. Serious adverse events related to treatment, including four versus one toxic deaths, were higher in the CTX arm (19% v 3%, P = .044). Locoregional control, patterns of failure, and survivals were similar between the treatment arms. Conclusion: CTX concomitant to RT lowered compliance and increased acute toxicity rates. Efficacy outcomes were similar in both arms. These results raise the issue of appropriately selecting patients with head and neck cancer who can benefit from CTX in combination with RT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2015.63.1671

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 214

Metadata

Authors
Magrini, S. M., Buglione, M., Corvò, R., Pirtoli, L., Paiar, F., Ponticelli, P., Petrucci, A., Bacigalupo, A., Crociani, M., Lastrucci, L., Vecchio, S., Bonomo, P., Pasinetti, N., Triggiani, L., Cavagnini, R., Costa, L., Tonoli, S., Maddalo, M., & Grisanti, S.
Venue
Journal of Clinical Oncology
Published
2016-02-10
Volume
34
Issue
5
Pages
427-435
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2194286561
Cited by
214
References
1
FWCI
29.46
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial. https://app.cochat.ai/papers/10.1200/jco.2015.63.1671
The paper
Magrini, S. M., Buglione, M., Corvò, R., Pirtoli, L., Paiar, F., Ponticelli, P., Petrucci, A., Bacigalupo, A., Crociani, M., Lastrucci, L., Vecchio, S., Bonomo, P., Pasinetti, N., Triggiani, L., Cavagnini, R., Costa, L., Tonoli, S., Maddalo, M., & Grisanti, S. (2016). Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.63.1671

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.